This article was originally published in The Tan Sheet
Executive SummaryThe joint Nonprescription Drugs and Metabolic & Endocrinologic Drugs Advisory Committee meeting on the Rx-to-OTC switch of Merck's Mevacor 20 mg will be webcast live beginning at 8 am on Jan. 13 and 14 from Bethesda, Md. For more information, call 1-800-627-8171...
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.